Teva might launch generic Lipitor: Analysts

December 2nd, 2011|

Israel based pharmaceutical company Teva, the world's biggest generic drug maker, will reportedly be able to exclusively distribute its version of the Lipitor cholesterol-lowering medicine due to its collaboration with Indian pharmaceutical company Ranbaxy, which holds a 180-day permit to distribute the generic drug, Calcalist , it is learned.

Light fights against Cancer

December 2nd, 2011|

Researchers in U.S have discovered that light could be a “promising” tool in the fight against cancer, without damaging the surrounding tissues. They described how a drug could be created which sticks to tumors, but is activated only when hit by specific waves of light.

Coffee lowers risk of Skin Cancer

December 2nd, 2011|

According to a research by American Association for Cancer Research, people who drink coffee are at a reduced risk of developing Basal Cell Carcinoma, the most common form of skin cancer. And the more they drink lesser the risk !!

Indian pharmaceutical industry has tremendous potential to grow from the current levels

February 19th, 2010|

A highly organized sector, the Indian pharmaceutical industry is estimated to be worth $4.5 billion, growing at about 8% to 9% every year.

Brit scientists find way to store vaccines in room temp

February 18th, 2010|

Scientists may have finally found a way to deal with one of developing world's worst problems in healthcare — faulty and inadequate cold chain for vaccine storage. British scientists from Oxford University have found a way to keep vaccines stable even in room temperature.

GlaxoSmithKline Pharma: In sound health

February 18th, 2010|

Sales growth and control on costs helped improve margins.Improved sales across its four business units helped GlaxoSmithKline Pharmaceuticals record an 18 per cent year-on-year growth in gross sales to Rs 453 crore for the December 2009 quarter. This, coupled with lower excise outgo, helped the company post a better-than-expected 20 per cent year-on-year jump in net sales.

Reddy formula

February 18th, 2010|

If a shareholder had invested about Rs 2,500 in Dr Reddy's Laboratories through the IPO in August 1986 and the rights issue of 1989, what do you think the holding would be worth today? A whopping Rs 40 lakh!

Pharmaceutical Advantage For India

February 18th, 2010|

The Indian drug industry could make huge gains as over $70 billion worth of drugs are expected to go off patent in the US, the world’s largest pharma market, in the next three years.

Sanofi aventis extends pact with Aureus Pharma for licence of DDI Predict 2009 Edition application

February 18th, 2010|

Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery and development in the life sciences industry, announced the extension of its agreement with sanofi-aventis for the licence of the DDI Predict 2009 Edition application.

Dishman joins hands with Californian firm

February 18th, 2010|

Ahmedabad based Contract Research and Manufacturing Services (CRAMS) major Dishman Pharmaceuticals and Chemicals Ltd has entered into a strategic alliance with California based biotechnology firm Codexis, Inc. that will allow Dishman to use of Codexis' proprietary enzymatic biocatalysis technology to manufacture intermediates and active pharmaceutical intermediates (APIs).

Russia invites Indian pharmas for joint ventures

February 16th, 2010|

Russia today invited Indian pharmaceutical companies to set up joint ventures in the country.

Pharma industry deserves priority status

February 16th, 2010|

In this arena, we believe there should be two broad priorities for India. First, to ensure that there is timely access to affordable quality medicine for the underprivileged. Second, due to the global scale and impact of the Indian pharmaceutical industry, to ensure that we give it the most comprehensive support that it deserves.

MDS selling Pharma Services unit for 45 million US dollars

February 16th, 2010|

Medical research firm MDS Inc. is selling its Pharma Services Early Stage unit to two private equity firms for $45 million.

Pharmaceutical Giants AstraZeneca (AZN), Rigel (RIGL) Collaborate On Arthritis Drug

February 16th, 2010|

According to a report, UK based Pharma company AstraZeneca PLC (ADR) (NYSE: AZN), and US based Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) plan to develop a drug to treat rheumatoid arthritis.

Biogen Idec lines up big India push

February 15th, 2010|

Like pharma giants Pfizer, Eli Lilly and Merck & Co, US biotechnology major Biogen Idec also doesn’t want to miss the India opportunity.

GSK sees growth shot in vaccines

February 15th, 2010|

For GSK Pharmaceuticals Ltd, vaccines is clearly a major focus area, currently constituting about 8% of total sales.

Indian pharma in midst of corporate transformation

February 15th, 2010|

Surging growth and global operations ensure they can’t be family-run any longer.

3SBio ties up with Ascentage Pharma to develop and commercialize cancer therapeutics

February 15th, 2010|

3SBio Inc, a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. to organise job fair for healthcare and pharma in Mumbai

February 15th, 2010|, India’s No. 1 job portal for Healthcare and Pharma industry, will be organizing an exclusive ‘Healthi Job Fair 2010’ for Healthcare and Pharma 'Healthi Job Fair 2010' at the Bombay Exhibition Center, Western Express Highway, Goregaon East, Mumbai on March 20 and 21, 2010.

From Oceans to Crops, and From Crops to IPO

February 14th, 2010|

Avesthagen’s systems biology approach to novel products targets more than land based organisms – dives deep into new products from the OceanAvesthagen has always been in the forefront of innovative scientific thinking and has developed a formidable portfolio of patents in all the four areas it operates in viz. bioAgriculture, bioNutrition, bioPharmacueticals and in Science & Innovation.  Approximately 600 patent applications cover both, process and products. There are several copyrights and design patents as well.  Within each area Avesthagen aspires to benefit the common man, and more so for the “bottom of the pyramid”.